Biotechnology News and Research

RSS

Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis

Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Life Technologies reports fourth-quarter and fiscal year results ended December 31, 2009

Life Technologies Corporation today announced results for its fourth quarter and full year ending December 31, 2009. Non-GAAP revenue for the fourth quarter was $874 million, resulting in full year non-GAAP revenues of $3.30 billion, an increase of 5 percent over the $3.14 billion reported for 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 28 Jan 2010

Cenduit announces strategic business alliance with invivodata

Cenduit, LLC, and invivodata, inc., today announce a strategic business alliance to further improve clinical trial efficiencies by adding the scientific and operational benefits of invivodata’s electronic Patient Reported Outcomes (ePRO) solutions to the proven efficiencies of Cenduit‘s Interactive Response Technology solution (IRT).

28 Jan 2010

Baxter International reports net income of $572M for the fourth-quarter of 2009

Baxter International Inc. today reported strong performance for the fourth quarter of 2009, and provided its financial outlook for the first quarter and full-year 2010.

From Baxter International Inc. 28 Jan 2010

Repligen announces five-year supply agreement for recombinant Protein A with GE Healthcare Bio-Sciences

Repligen Corporation announced today that it has extended its longstanding relationship with GE Healthcare Bio-Sciences AB by entering into a five-year supply agreement for recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical. Repligen is the world's leading supplier of recombinant Protein A and has manufactured recombinant Protein A for GE Healthcare for more than 10 years.

28 Jan 2010

Formatech donates $308K in aseptic liquid fill and finish manufacturing services

Formatech continues its pledge to give back and make a difference in the biotechnology and pharmaceutical community with its Fillanthropy Program. Since the program’s inception, Formatech has donated $308K in aseptic liquid fill and finish manufacturing services to companies developing new drug therapies.

28 Jan 2010

New insight into reprogramming of cells

A discovery by Babraham scientists brings new insight into how cells are reprogrammed and a greater understanding of how the environment, or factors like nutritional signals, can interact with our genes to affect health. As an embryo develops, cells acquire a particular fate, for example becoming a nerve or skin cell. The findings, reported online in the journal Nature, pinpoint a protein called AID as being important for complete cellular reprogramming in mammals.

28 Jan 2010

New research findings may lead to new treatment options for abdominal aortic aneurysms

New research findings from a team at the Providence Heart + Lung Institute at St. Paul's Hospital and the University of British Columbia (UBC) may lead to new treatment options for abdominal aortic aneurysms (AAA) - a potentially fatal disease that currently has no pharmacological treatments.

28 Jan 2010

Life Technologies announces a series of investments and new technologies for genetic sequencing research

Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science solutions, today announced a series of investments and new technologies designed to extend the use of sequencing in the research arena and make it more relevant for physicians.

28 Jan 2010

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.

28 Jan 2010

ALS TDI and Oxford BioMedica extend collaboration to develop gene therapies for Lou Gehrig's disease

The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

28 Jan 2010

NIH to perform exploratory studies on ImmuneRegen BioSciences' Homspera

ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced the execution of an agreement with the National Institute of Health (NIH) / National Cancer Institute (NCI) to commence studies utilizing ImmuneRegen's Homspera.

28 Jan 2010

Imagine Media signs non-binding LOI to acquire DMI Life Sciences

Imagine Media, Ltd., a Delaware corporation today announced that it has signed a non-binding Letter of Intent to acquire DMI Life Sciences, Inc., a Denver, Colorado-based biotechnology company. (“DMI”). Under the terms of the LOI, if the acquisition is completed, the shareholders of DMI will acquire approximately 90.52% of the total issued and outstanding shares of the Company, and the transaction will constitute a change in control.

27 Jan 2010

Juvaris BioTherapeutics completes second close on its Series B equity financing

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed a second close on its Series B equity financing of up to $25 million. The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.

27 Jan 2010

International Stem Cell joins StockProfile.com

International Stem Cell Corporation, announced today that it has expanded its market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.

27 Jan 2010

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it is discontinuing development of ozarelix in benign prostatic hypertrophy (BPH).

27 Jan 2010

US PTO grants new allowances to intellectual property covering Neurologix' GAD based delivery systems

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix’s Parkinson’s disease program. The new allowances to U.S. Patent Number 765,446, entitled “Glutamic acid decarboxylase (GAD) based delivery systems,” broaden the patent’s coverage beyond Parkinson’s disease to include the use of GAD65 in the treatment of other neurological and related disorders.

27 Jan 2010

New technology could aid in developing novel drugs and future gene therapies

Researchers in Manchester have successfully carried out the first rewire of genetic switches, creating what could be a vital tool for the development of new drugs and even future gene therapies.

From The University of Manchester 27 Jan 2010

Findings provide new insight into factors causing neurodegenerative diseases

Scientists at the Babraham Institute have discovered a novel survival factor whose rapid transport along nerve cells is crucial for keeping them alive. The same factor seems likely to be needed to keep our nerves healthy as we age.

27 Jan 2010

Biotechnology News and Research

Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Life Technologies reports fourth-quarter and fiscal year results ended December 31, 2009

Cenduit announces strategic business alliance with invivodata

Baxter International reports net income of $572M for the fourth-quarter of 2009

Repligen announces five-year supply agreement for recombinant Protein A with GE Healthcare Bio-Sciences

Formatech donates $308K in aseptic liquid fill and finish manufacturing services

New insight into reprogramming of cells

New research findings may lead to new treatment options for abdominal aortic aneurysms

Life Technologies announces a series of investments and new technologies for genetic sequencing research

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

ALS TDI and Oxford BioMedica extend collaboration to develop gene therapies for Lou Gehrig's disease

NIH to perform exploratory studies on ImmuneRegen BioSciences' Homspera

Imagine Media signs non-binding LOI to acquire DMI Life Sciences

Juvaris BioTherapeutics completes second close on its Series B equity financing

International Stem Cell joins StockProfile.com

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

US PTO grants new allowances to intellectual property covering Neurologix' GAD based delivery systems

New technology could aid in developing novel drugs and future gene therapies

Findings provide new insight into factors causing neurodegenerative diseases

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News